NCT04703166View on ClinicalTrials.gov

Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.

RecruitingOBSERVATIONAL
Enrollment

360

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial Fibrillation
Interventions
DEVICE

Samsung Galaxy Watch Active2

The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.

Trial Locations (1)

70112

RECRUITING

Tulane University School of Medicine, New Orleans

Sponsors

Collaborators (1)

Preventice
All Listed Sponsors
collaborator

Samsung

INDUSTRY

collaborator

Preventice

INDUSTRY

lead

Tulane University School of Medicine

OTHER

NCT04703166 - Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy. | Biotech Hunter | Biotech Hunter